Showing items tagged as 21 CFR Part 11

  • 2021-bl-annex11-vs-part11_132x132

    Understanding the EU’s Annex 11 and FDA’s 21 CFR Part 11

    With manufacturers digitizing at a rapid rate, understanding the core of the European Union’s (EU) guidelines, Annex 11, and its approximate FDA counterpart, 21 CFR Part 11, is more critical than ever. They are central to understanding the conditions for life sciences manufacturers’ electronic data in the EU and the U.S., and while the guidance is similar in both countries, it’s important to understand the key differences.

    Full story
  • quality-control-approval-with-abstract-background-132

    Life Sciences Start-Ups: What You Need to Know About Phase Appropriate Quality Requirements

    Whether your start up company makes pharmaceutical products, biologics, or medical devices, you all have one thing in common. You need to implement a robust digital quality management system (QMS) at the early phase of product development to comply with the ever changing and more stringent regulations throughout the product life cycle.

    Full story
  • 2021-bl-cfr-part-11_132x132

    20 Years Later, 21 CFR Part 11 is More Relevant than Ever

    The U.S. Food and Drug Administration’s (FDA) 21 CFR Part 11 guidance made electronic records and signatures as valid as paper records and handwritten signatures. The guidance changed the dynamic of data and records management by advocating modernized technology in the life sciences industry.

    Full story
  • 2021-bl-compliance-checklist_132x132

    Q&A: A Risk-Based Approach to Compliant Audit Trails

    More regulated companies have transitioned to maintaining records and submitting information electronically. This involves tight data and records management and audit trails. In this article, Seyed Khorashahi, executive vice president of medical devices and CTO at Regulatory Compliance Associates (RCA) Inc., shares valuable insight on the anatomy of an audit trail and advises companies on how to comply with this critical component of 21 CFR Part 11.

    Full story
  • 2020-bl-gxp-lifeline-template_132x132

    Simplifying Part 11

    21 CFR Part 11 went into effect more than 20 years ago, and it remains a widely discussed regulation.

    Full story
  • 2019-bl-thumb-purpose-bulit-manufacturing-systems

    Understanding GxP Predicate Rules Is Key to Compliance With FDA 21 CFR Part 11

    FDA 21 CFR Part 11 does not invalidate the predicate rules that were established for paper-based document management systems, it simply builds upon and reinforces those existing rules in digital platforms. Learn about the symbiotic nature of Part 11 and FDA predicate rules and discover how an awareness of their relationship is fundamental to easing compliance burdens.

    Full story
  • 2020-bl-arbour-day-group_thumb

    The Challenges of Cloud Compliance in a Regulated Environment

    Life sciences companies are migrating the cloud. To be successful with cloud compliance in a regulated environment, it’s important to understand the key challenges and know how to address them. While cloud host providers offer security features, it is your organization’s responsibility to confirm the provider is compliant.

    Full story
  • 2020-bl-thumb-three-c-in-covid-19

    Three C’s That Will Matter for Manufacturers in a ‘Post-COVID-19’ World

    The time for manufacturers to prepare for a post-COVID-19 world is now. Re-calibrate for the "new normal" by looking to these "three c's" for guidance.

    Full story
  • 2020-bl-thumb-data-integrity-and-21-cfr-part-11

    How Harmonizing 21 CFR Part 11 and Data Integrity Delivers Higher Quality Products

    Complying with the many record and data management requirements for 21 CFR Part 11 and data integrity can be daunting. In this article, Matt Brawner, data integrity subject matter expert (SME) at Sequence Inc., explains how companies can integrate Part 11 and data integrity processes to accelerate pathways to approval and deliver higher quality products to market.

    Full story
  • 2019-bl-thumb-data-integrity

    Data Integrity: Trends, Pitfalls, Solutions, and Why DI Is Still Making Headlines

    In a modern, technological era with an ever-increasing amount of data and data systems, robust data integrity is crucially important, particularly for life science and other regulated industries. Learn the latest best practices to properly ensure that you company’s data is complete, consistent and accurate.

    Full story
  • 2018-bl-thumb-regulatory-barriers-for-biotech-medtech-startups-europe

    Regulatory Barriers to Innovation for Startups

    France and Europe are witnessing an explosion of life science innovation from new startups. But what separates the winners from the losers? Learn how to successfully overcome regulatory barriers and get your product to market quicker.

    Full story
  • 2018-bl-thumb-manufacturing-software-trends-july-2018

    The #1 Gap in Manufacturing Software Today

    It’s 2018 and technology has pervaded every area of our lives. Yet a visit to almost any manufacturing floor reveals that paper is alive and well, even in forward-thinking companies with strong IT strategies and digital transformation initiatives in place. Why is it that the truly paperless factory floor remains so elusive?

    Full story
  • 2016-nl-bl-thumb-cfda

    Necessity Is the Mother of a Groundbreaking Validation Tool

    It has been proven time and again that necessity is the mother of invention. From the printing press to electric cars, the story is similar. The printing press answered the need for a more rapid dissemination of information during the Renaissance, while the electric car is a response to the need for a zero-emission car today. In regulated environments, the dire need to lighten the software validation burden led to the development of a groundbreaking application.

    Full story
  • 2018-bl-thumb-eus-gdpr

    GDPR Deadline Approaches: What Is Expected for Compliance?

    First the bad news. As long as health care-related data remains a valuable commodity, security breaches and data theft will persist. The good news is global regulatory agencies are ramping up their cybersecurity measures in an effort to restore relevance to the “protection” component of protected health information (PHI).

    Full story
[ { "key": "fid#1", "value": ["GxP Lifeline Blog"] } ]